While lung transplantation is an attractive treatment option for many end stage lung diseases, the relatively high 5-year mortality continues to be a significant limiting factor. Among the foremost reasons for this is the eventual development of obstructive chronic lung allograft dysfunction. Infections, which the lung allograft is especially prone to, are a major risk factor. Specifically, the Aspergillus species cause a higher burden of disease among lung transplant recipients, due to unique risk factors, such as relative hypoxemia. However, these risk factors also provide unique opportunities for treatment and preventative strategies, as outlined in this review.
Introduction
Lung transplantation (LTx) is a viable treatment option for a number of end stage pulmonary pathologies. The number of LTx's has been steadily increasing, with a total of 3,893 transplants performed in 2013 based on data from the International Society for Heart and Lung Transplant (ISHLT) registry. 1 The median survival following LTx is 5.7 years, which is considerably lower than many other solid organ transplants, despite advances in surgical technique, immune suppressive regimens, and opportunistic infection prophylaxis. 1 The leading cause of death 1 year after LTx is infection with bacterial, fungal, and viral organisms. 1 Infection with Aspergillus species is particularly serious, as it increases the risk for developing obstructive chronic lung allograft dysfunction (CLAD, also known as obliterative bronchiolitis), the most common overall cause of death for persons after LTx. 2 In this review we will provide an overview of the spectrum of Aspergillus-related pulmonary diseases that occur in LTx patients, unique risk factors, and ongoing experimental interventions to minimize the burden of disease.
Clinical manifestations and consequences of Aspergillus in lung transplantation
Aspergillus sp. are ubiquitous environmental moulds that are rarely pathogenic in immunocompetent individuals. However, in the immunosuppressed lung transplant recipient, Aspergillus-related pulmonary diseases encompass a variety of clinical syndromes. This varies from other patient populations, such as those who are immunosuppressed following hematopoietic cell transplantation or after chemotherapy, who generally present with invasive pulmonary aspergillosis (IPA), rather than colonization. 3 In contrast, in LTx patients, Aspergillus pulmonary diseases include both invasive infections and fungal colonization that lead to significant morbidity and mortality. The most commonly implicated pathologic strain is Aspergillus fumigatus, due to the smaller size of its spores, allowing disease to occur in the distal airways. In a dual center study of LTx recipients, colonization with small conidia Aspergillus (≤3.5 μm) was associated with an increased risk of developing CLAD (HR 1.44, 95% CI 1.14-1.82, P = .002). 2 The incidence of Aspergillus-related pulmonary disease in LTx is estimated at 25-30%. 4 Invasive infections are much less common, with reported rates of 3-15%. 3 In the early posttransplant period, the most common clinical syndromes are tracheobronchitis or bronchial anastamotic infections that can result in bronchial dehiscence, leading to bronchial abscesses, or to the development of pneumothoraces. 5 After 3 months, the most common presentations are IPA or systemic infections. 3 Mortality is closely associated with the development of IPA. A previous review of Aspergillus infections in LTx patients noted that late onset development of Aspergillus was associated with higher mortality than early onset disease (57% vs. 28%, P = .045). However, this finding was no longer present if only patients with IPA were included in the analysis (73% vs. 71%). 6 Additional diseases associated with Aspergillus colonization in LTx include allergic bronchopulmonary aspergillosis (ABPA), a severe form of asthma; and aspergillomas, often occurring in the native lung in the single LTx (Fig. 1) . 7, 8 Management of Aspergillus infections is further complicated by the use the -azole class of antifungals, which may alter levels of immunosuppressives, due to the concurrent effect on the liver enzyme responsible for metabolizing both drugs, cytochrome P450, isozyme CYP3A4. 9 Despite the health burden in LTx, little is known of the factors related to the host-pathogen relationship that explain the high incidence of Aspergillus-related pulmonary diseases in LTx. Proposed risk factors include: (i) the immunosuppressed state, (ii) poor airway clearance with a lack of a cough reflex and a decreased function of the mucocilliary escalator after LTx, and (iii) a constant exposure of the graft to environmental pathogens. 10, 11 Based on our research, we have additionally identified other characteristics that may explain this unique predilection for Aspergillus syndromes in the LTx recipient, such as alloimmunemediated microvascular injury resulting in graft ischemia and hypoxia. inhibits host angiogenesis. 14 It is posited that the creation of an ischemic environment sequesters the pathogen from the host inflammatory response and likely contributes to its virulence. 12, 13, 15 Compared to other solid organs, the lung allograft is especially vulnerable to the effects of graft ischemia. The pulmonary vasculature consists of the oxygen rich bronchial arterial vessels and the oxygen deplete pulmonary arterial vessels. 16 Following transplantation, only the pulmonary vessels are re-attached, as shown in Figure 2 . As anticipated, this loss of dual vascular supply leads to a prolonged period of relative hypoxemia in the allograft, despite preferential flow of the pulmonary arterial circulation to the transplanted lung (in single organ transplantation).
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Alloimmune-mediated microvascular injury, as described below, creates ischemic tissues that may provide a substrate for the growth of microorganisms analogous to the devascularized tissues of diabetic patients, promoting chronic infections. The findings of alloimmune-mediated microvascular loss shown in the murine orthotopic tracheal transplant (OTT) model are consistent with the observation by Luckranz et al., of chronic small vessel loss in the lower airways of lung transplant patients prior to the development of CLAD. 18 The effects of this relative ischemia include airway stenosis, and an increased incidence of infections. [17] [18] [19] [20] An earlier study noted similar findings, and suggested that re-attachment of the bronchial arterial vasculature may delay the development of obliterative bronchiolitis. 21 Because of the mould's angiotropic nature and capacity to thrive under hypoxic conditions, we hypothesized that the degree of A. fumigatus invasion would increase with the progressive ischemia of the rejecting allograft. 13, 14, 22 With this view, alloimmune-mediated ischemia, working in concert with Aspergillus infection, can be seen as a unique and critical host-pathogen factor post-LTx that promotes both poor anastomotic wound healing and pathogen virulence.
A potential role of the alloimmune response in promoting fungal infection While activation of the innate immune system promotes the alloimmune response, the same components are crucial for host protection from Aspergillus. In an immune competent host, the innate immune system recognizes pathogens via pattern recognition receptors. This causes recruitment of alveolar macrophages, which phagocytose A. fumigatus spores, and via the production of intracellular reactive oxygen and nitrogen species, destroy engulfed spores. This, consequently, prevents germination and further proliferation of the mould. In addition, A. fumigatus infection promotes recruitment of neutrophils, which prevent infection by either phagocytosing the spores or via extracellular lysis due to release of toxic granules. Given that the vasculature, specifically capillaries, are a known reservoir for neutrophils, 28 damage to blood vessels via alloimmune mediated rejection, as outlined above, may result in a relative paucity of neutrophils, possibly explaining the increased Aspergillus invasion noted in allogeneic transplants.
Among the components of the adaptive immune system studied in the OTT model, CD4
+ T cells play a key role in the development of persistent microvascular injury. 26 It has been recently elucidated that T-cell responses in lung transplant rejection include T regulatory cells, follicular T cells, and Th17 cells. Recently, Th17 cells have been implicated in lung transplant rejection and the concentration of interleukin 17 (IL-17), a Th17-associated cytokine, in bronchoalveolar lavage fluid has been associated with the severity of chronic rejection. 29 Conversely, a heightened Th17 response has been associated with promoting fungal infection with A. fumigatus. 30 Thus a skewed Th17 response during chronic LTx rejection may provide a link between alloimmunity and the high incidence of mould infections post-LTx. This observation requires further investigation, as it may offer additional treatment strategies in the immunocompromised individual. Therefore, work is ongoing to define the role of alloimmunity in it contribution to pathogen virulence.
Aspergillus fumigatus invasion increases with progressive allograft ischemia
Using the OTT model of A. fumigatus infection, we evaluated the host-pathogen interaction in transplantation.
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The OTT model, due to the planar anatomy of the trachea, allows for a detailed study of the microvasculature in transplantation as blood vessels are linearly displayed in two dimensions, in contrast to the complex anatomy of vessels in terminal airways, which are difficult to capture by histological techniques. 24, 26, 27, 32 While not an exact clinical replica of lung transplantation, the resulting fibrosis observed in the OTT model does replicate lymphocytic bronchiolitis, which is thought to be a precursor to CLAD. Thus, an A. fumigatus infection in the OTT is an ideal model for studying the role of ischemia in promoting pathogen virulence. Acutely rejecting tracheal transplants undergo a series of distinct microvascular events including: (i) reperfusion of the donor graft from reanastomosis with recipient vessels that is partially dependent on hypoxia inducible factor (HIF) pathways at day 4 post-transplant, (ii) progressive alloimmune microvascular damage due to CD4 + T cells and independently complement after day 6 post-transplant, (iii) profound rejection-mediated ischemia between days 10 and 14, followed by (iv) recipient-derived neovascularization. 17, 25, 26 Using the OTT model we studied the role of ischemia and hypoxia in promoting A. fumigatus allograft invasion, a marker of pathogen virulence. 23 Laser Doppler flowmetry and FITC-lectin immunofluorescence were used to determine blood perfusion, and a fiber optic microsensor was used to measure airway tissue oxygen tension. Fungal burden and depth of invasion were graded using histopathology. We demonstrated that: (i) the OTT model recapitulates the tracheal infections observed clinically in LTx patients with infection localizing to the airway anastomosis, (ii) A. fumigatus infection modulates regional blood perfusion, (iii) in syngeneic transplants, the mould displays a colonization phenotype, and (iv) the depth of A. fumigatus invasion increases with progressive allorejection-mediated vascular ischemia and hypoxia. 23 Taken together, these findings suggest that graft ischemia and hypoxia or a factor-related to alloimmune microvascular injury may promote a more invasive A. fumigatus phenotype.
The clinical relevance of our study could possibly extend beyond LTx to elucidate, in part, the presentation of the mould in other forms of Aspergillus-related pulmonary diseases. One difference among individuals who develop the disparate forms of Aspergillus lung diseases is the variability of the health of the bronchial circulation. In cystic fibrosis and asthmatic patients, the bronchial arterial network is robust resulting in a hypervascularity of the airways. 10, 33 In these persons, A. fumigatus typically displays a colonization phenotype, rarely invading tissues. In patients with chronic obstructive pulmonary disease (COPD), there is a slowly progressive destruction of the microvasculature and in these hosts A. fumigatus exhibits a more indolent invasive infection known as chronic pulmonary aspergillosis. 33, 34 Similarly, among LTx patients, ischemia due to the failure to restore the bronchial circulation and surgical disruption of the vasculature may result in tracheal anastomotic infections early. Additionally, in the later posttransplant period, progressive microvascular loss associated with chronic rejection may lead to the development of IPA. While these observations are thought provoking, further studies are needed to establish causality. An increased understanding of the role of the bronchial circulation in maintaining host defenses may provide novel treatments such as bronchial artery restoration or promotion of microvascular health and thus may possibly ameliorate the burden of these infections.
Novel strategies to minimize A. fumigatus pathogenicity
Given the morbidity associated with A. fumigatus in the LTx recipient, minimizing the pathogenicity of this organism is of clinical importance. While antifungal medications are the current preferred treatment option, their use is not without side effects in LTx and may not always be effective given an increasing prevalence of azole resistant Aspergillus strains. 35 Therefore, contemporary research has also focused on modifiable risk factors, such as hypoxemia and ischemia.
Minimizing the effects of hypoxia in the lung allograft is accomplished either by increasing oxygen supply or by blocking the alloimmune-mediated microvascular damage that results in graft ischemia and hypoxia. Among the proposed interventions to increase oxygen supply, reconnection of the bronchial arterial system, also known as bronchial artery revascularization (BAR) is likely the most promising. Pettersson et al. compared outcomes of LTx patients with and without BAR.
19 At 1 year follow-up, patients who underwent BAR had significantly fewer pulmonary (P < .04) and bloodstream infections (P < .02) than those that did not undergo BAR. 19 However, BAR is not widely accepted by the surgical LTx community, due to concerns: for increased ischemic time for the transplanted organ, for higher rates of bleeding complications, and other technical considerations. 16 As an alternative to BAR, our research group has focused on mitigating the alloimmune-mediated microvascular injury that occurs post-LTx. The cellular response to hypoxemia involves various changes to cellular metabolism, proliferation, apoptosis, and angiogenesis. 36 Hypoxia inducible factor (HIF) governs the family of transcription factors that regulate these responses. 37 There are three known members, though most research has focused on HIF-1 and HIF-2. These transcription factors consist of an α and a β subunit (as shown in Fig. 3) . 38 In normoxia, the α subunit is hydroxylated by prolyl hydroxylase domain proteins, which is recognized by the von Hippel-Lindau (VHL) protein and subsequently marked for proteosomal degradation. 39 Expression of HIF is therefore heavily dependent on VHL. In hypoxic conditions, however, the α subunit does not become hydroxylated, and instead binds to the β subunit, forming a heterodimer. This complex then binds near the promoter regions of hypoxia sensitive genes, resulting in gene transcription and subsequent release of various angiogenic factors and other cellular actions as noted above. 40 Using the OTT model, we studied the role of VHL knockdown in the transplant recipient, as a means of increasing HIF-1α, to promote microvascular repair posttransplantation and to mitigate A. fumigatus invasion. 31 In these studies, we transplanted tracheas into mice with VHL haplodeficiency in Tie2 positive cells, a marker for cells of endothelial and myeloid lineage. Increased HIF-1α as a result of VHL haplodeficiency prolonged airway microvascular perfusion and promoted tissue perfusion through the production of the angiogenic factors, SDF-1 and angiopoietin 1. 31 By contrast, in recipient mice with HIF-1α deficiency in Tie2 lineage cells, microvascular repair was significantly diminished. Comparing VHL-haplodeficient mice with wild-type controls, in 83% of the recipients with increased HIF-1α, A. fumigatus was noninvasive in contrast to 75% of wild-type mice (with lower HIF-1α) in which the mould was deeply invasive. 31 Thus, stabilization of the HIF-1α in endothelial cells, through Tie2 cell VHL haplodeficiency, promoted airway microvascular regeneration and vascular normalization, minimizing tissue ischemia and hypoxia, which correlated with a diminished A. fumigatus virulence. 27 While the putative effector of HIF-1α in our studies is the endothelial cell, Shepardson et al. demonstrated increased A. fumigatus virulence in animals with a knockout of HIF-1α in myeloid cells. 41 In this study they demonstrated that HIF-1α is required for murine survival from IPA, by allowing myeloid cells to maintain immune cell recruitment during infection. 41 Because the Tie2 marker used in our study is expressed on cells of both myeloid and endothelial lineage, work is ongoing to further elucidate the role of HIF-1α and its effector cell type in protecting against A. fumigatus infection.
Conclusion
One in three persons post-LTx suffer from an Aspergillusrelated pulmonary disease. Aspergillus infections lead to numerous complications associated with both fungal colonization and tissue invasion. There are a number of pathogen and host specific factors that predispose this population to Aspergillus-related pulmonary diseases, including relative hypoxemia, allograft ischemia and potentially alloimmune-mediated dysregulation of the host immune defense against the pathogen. However, these unique risk factors may also serve as novel therapeutic targets. Current research has focused on mechanisms to modulate these risk factors in the lung allograft, with promising results.
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